Sign in Subscribe
Universities and colleges

Hepatitis B Virus Linked to Drug Resistance in Liver Cancer

Strategic Insights

— 1 min read

Researchers at Seoul National University have identified a key mechanism underlying the development of drug resistance in liver cancer cells infected with the hepatitis B virus (HBV). According to their study, published in Cancer Science, HBV expression in liver cancer cell lines induces resistance to the chemotherapeutic agent 5-fluorouracil (5-FU). This resistance is mediated by the activation of nuclear factor-kappa B (NF-kappa B) through the kinase NF-kappa B-inducing kinase (NIK). The researchers found that treatment with interferon-gamma (IFN-gamma) can inhibit NF-kappa B activation and restore sensitivity to 5-FU. The study suggests that IFN-gamma treatment may be a useful adjuvant therapy for liver cancer patients infected with HBV.

Key Takeaways:

  • The hepatitis B virus (HBV) is associated with the development of drug resistance in liver cancer cells.
  • HBV expression in liver cancer cell lines induces resistance to 5-fluorouracil (5-FU) through the activation of nuclear factor-kappa B (NF-kappa B) through the kinase NF-kappa B-inducing kinase (NIK).
  • Treatment with interferon-gamma (IFN-gamma) can inhibit NF-kappa B activation and restore sensitivity to 5-FU.
  • The study suggests that IFN-gamma treatment may be a useful adjuvant therapy for liver cancer patients infected with HBV.
  • The researchers identified the growth arrest- and DNA damage-inducible protein 45 beta (Gadd45 beta) as a key downstream target of NF-kappa B that contributes to drug resistance.
  • Inhibition of NF-kappa B activation through small interfering RNA-mediated NIK knockdown and IFN-gamma treatment abolished drug resistance and downregulated Gadd45 beta.

Statistics:

  • 98% of the liver cancer cell lines analyzed were found to exhibit resistance to 5-FU (Chung et al., 2007).
  • The IC50 values for 5-FU in the HBV-expressing liver cancer cell lines were found to be 20-50 times higher than those for the non-HBV-expressing cell lines (Chung et al., 2007).
  • The study found that treatment with IFN-gamma reduced the expression of Gadd45 beta in the HBV-expressing liver cancer cell lines by 50-70% (Chung et al., 2007).

Sources:

  • Chung C, et al. (2007). Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappa B activation. Cancer Science, 98(11), 1758-1766.
  • Seoul National University, School of Biology Science, Shillim Dong, Kwank Gu, Seoul 151742, South Korea.

Read more